Plexxikon Inc. Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients
11/9/2012 9:57:57 AM
More...
|
Plexxikon Inc. Announces European Approval of Zelboraf® for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
2/21/2012 6:49:47 AM
More...
|
Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood Cancer
12/13/2011 6:53:20 AM
More...
|
Plexxikon Inc. Advances Novel Targeted Treatment PLX3397 in Blood Cancer
12/12/2011 12:17:21 PM
More...
|
Plexxikon Inc. Novel Agents Aim to Address Cancer Treatment in New Ways
11/14/2011 9:49:40 AM
More...
|
Plexxikon Inc. Announces Combination Trials for Vemurafenib in Melanoma
6/2/2011 10:55:07 AM
More...
|
Plexxikon Inc. Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at American Society of Clinical Oncology 2011 Annual Meeting
5/18/2011 9:52:57 AM
More...
|
Plexxikon Inc.: New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma
5/11/2011 10:20:00 AM
More...
|
Daiichi Sankyo, Inc. (D4S.F) Completes Plexxikon Inc. Acquisition
4/4/2011 8:50:18 AM
More...
|
Plexxikon Inc. Selects Clinipace Worldwide to Manage Four Clinical Trials
3/15/2011 9:14:54 AM
More...
|
|